Skudexa 75 mg FC tablet.
PDF Leaflet Revision Date: 04 July 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Short-term treatment of moderate to severe acute pain.
Dosage (summary)
1 tablet every 8 hours, max 3 tablets/day for adults; 2 tablets/day for elderly.
Onset of Action / Duration
Onset: 30 mins, Duration: 6-8 hours
Special Populations
- Elderly
- Hepatic impairment
- Renal impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation.
Key Drug Interactions
- Anticoagulants
- Other NSAIDs
- MAO inhibitors
Contraindications
- Hypersensitivity to components
- Severe hepatic impairment
- Moderate to severe renal impairment
Common side effects
- Nausea
- Dizziness
- Abdominal pain
Counselling Points
- Take with water 30 mins before meals
- Limit use to 5 days
- Monitor for signs of gastrointestinal issues
Serious warnings
- Risk of gastrointestinal bleeding
- Respiratory depression
- Potential for addiction
Important Disclaimer
The Skudexa 75 mg FC tablet. professional information leaflet below is the property of Lebasi Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
